Definitive and Indicative Stages Sample Clauses

Definitive and Indicative Stages. 3.2. Stages 1-5, leading up to and including deposit, are under the direct control of the Council, which will make every effort to adhere to this part of the timetable (see paragraphs 2.15-2.25).
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Definitive and Indicative Stages. As stated in paragraph 2.1 above the RLDP the timetable has two stages: the ‘Definitive Stage’ (Stages 1-5) and the ‘Indicative Stage’ (Stage 6-10).
Sample 1Sample 2Sample 3
Definitive and Indicative Stages. The Timetable is split into two stages for the production of the LDP – stage one contains definitive dates and stage two contains indicative dates.
Sample 1Sample 2Sample 3
Definitive and Indicative Stages. 4.2.1 The LDP Regulations provide for a two-stage timetable – definitive stage and indicative stage.
Sample 1Sample 2
Definitive and Indicative Stages. As stated in paragraph 2.1 above the LDP the timetable has two stages: the ‘Definitive Stage’ (Stages 1-5) and the ‘Indicative Stage’ (Stage 6-10). Figure 2.2 - Draft Timetable for the Torfaen Local Development Plan Review Key LDP Work Preparation LDP Preparation Consultation LDP Reporting - Decision Making Stage - Statutory Instrument Stage Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Review of LDP (Reg. 41) Stage 1 Preparation of LDP Review Report 1 Council approval to consult on Review Report 2 Consultation on LDP Review Report 3 Full Council Approval of LDP Review Report 4 Submit to Welsh Government 5 Produce Delivery Agreement (Reg. 9) Stage 2 Prepare Draft DA - Timetable and CIS 6 Council approval to consult on Delivery Agreement 7 Consult on Draft DA 8 Full Council Approval of DA 9 Submit Draft DA to WAG 10 Welsh Government agree DA 11 Review & Update Evidence Base for LDP & SA/SEA (Pre Reg. 14) Stage 3 Review and updating of Evidence Base 12 Tender & Appoint Consultants for Background Studies 13 Key LDP Work Preparation LDP Preparation Consultation LDP Reporting - Decision Making Stage - Statutory Instrument Stage May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Pre Deposit Participation (Reg. 14) Stage 4 Call for Candidate Sites 14 Publication of Candidate Sites Register 15 Assessment of Candidate Sites - Stage 1A Assessment 16 Assessment of Candidate Sites - Stage 1B Assessment 17 Assessment of Strategic Sites - Stage 2 Assessment 17 Review existing Vision 18 Stakeholder engagement on LDP Vision and Objectives and Preparation of Report 19 Review of SA(SEA) Baseline Information 21 Review SA/SEA Objectives 22 Produce Draft Scoping Report 23 Consult with Consultation Bodies 24 Preparation of Strategic Options 25 Stakeholder engagement on Strategic Options 26 SA/SEA Assessment of Strategic options 27 Preparation of Preferred Strategy 28 Preparation of Initial Sustainability Appraisal Report 29 Report Preferred Strategy to Full Council 30 Key LDP Work Preparation LDP Preparation Consultation LDP Reporting - Decision Making Stage - Statutory Instrument Stage Sep-19 Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Pre Deposit Public Consultation (Reg.s 15/16) - Preferred Strategy Stage 5 Pre Deposit Public Consultation on Preferred Strategy, Vision, Strategic Options & K...
Sample 1
Definitive and Indicative Stages. As evident in Table 1, the LDP Regulations provide for a two-stage timetable – definitive stage and indicative stage. Definitive stages (stages 1-6) are those up to and including the Deposit Plan stage. As these stages are under the direct control of the Council, the timescales outlined above are considered to be realistic and achievable. Every effort will be made to adhere to and avoid deviations from the (agreed) timetable. Indicative stages (stages 7-12) relate to those stages of the LDP process post Deposit and up to and including Adoption. As this stage of the process is dependant on various external factors and influences, such as the number of deposit representations received, the dates are indicative. In accordance with the LDP Regulations, the Council will define the indicative timetable within 3 months of the close of the formal six week Deposit period (following entering into a service level agreement with the Planning Inspectorate).
Sample 1

Related to Definitive and Indicative Stages

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • EXTRA-CURRICULAR ACTIVITIES 1. In this agreement, extra-curricular programs and activities include all those that are beyond the provincially prescribed and locally determined curricula of the school.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Co-Curricular Activities G. The enrollment of the student of employees who reside outside the District shall be subject to School Board Policy 3.02(3)f, Out-of-County Students.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Trials The Ship shall run the following test and trials:

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

Time is Money Join Law Insider Premium to draft better contracts faster.